NCT04461795View on ClinicalTrials.gov

Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

January 10, 2022

Study Completion Date

January 10, 2022

Conditions
Migraine
Interventions
DRUG

Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]

225 MG/1.5 ML Subcutaneous Solution

Trial Locations (2)

63303

StudyMetrix, City of Saint Peters

65810

Clinvest Research, LLC, Springfield

All Listed Sponsors
lead

David True

INDUSTRY

NCT04461795 - Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden | Biotech Hunter | Biotech Hunter